Efficacy and tolerability of multiple drug therapy in HIV-infected children

Journal of Infection

Volumn 50, Issue 5, 2005, Pages 404-411

  Viganò, Alessandra ^a   Schneider, Laura ^a   Giacomet, Vania ^a   Bianchi, Roberta ^a   Cicero, Mirko Lo ^a   Soster, Francesca ^a   Bulgheroni, Elisabetta ^a   Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Efficacy; HIV infection; Multiple drug therapy; Pediatrics; Tolerability

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; GEMFIBROZIL; INDINAVIR; LAMIVUDINE; LEVOTHYROXINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ONDANSETRON; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENOTYPE; GOITER; HASHIMOTO DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; NAUSEA; NEUTROPENIA; PANCREATITIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS RESISTANCE; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PANCREATITIS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 18844423032     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.08.001     Document Type: Article

References (31)

1. F. Palella K. Delaney A. Moorman et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853-860
2. M. De Martino P.A. Tovo M. Balducci et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection JAMA 284 2000 190-197
3. J.S.G. Montaner P.R. Harrigan N. Jahnke et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens AIDS 15 1 2001 61-69
4. A.M.C. Van Rossum H.G.M. Niesters S.P.M. Geelen et al. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in the Netherlands J Pediatr 136 6 2000 780-788
5. A. Viganò L. Dally D. Bricalli et al. Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection J Pediatr 135 6 1999 675-682
6. S.A. Nachman K. Stanley R. Yogev et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children JAMA 283 2000 492-498
7. P. Krogstad S. Lee G. Johnson et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1 Clin Infect Dis 34 2002 991-1001
8. J.S. Montaner J.W. Mellors Antiretroviral therapy for previously treated patients N Engl J Med 345 2001 452-455
9. M. Youle M. Tyrer M. Fisher et al. Brief report: Two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen J Acquir Immune Defic Syndr 29 2002 58-61
10. S. Staszewski P. Gute A. Carlebach et al. Virological and immunological response to mega-HAART salvage therapy after failure of multiple antiretroviral regimens AIDS 12 Suppl. 4 1998 S40
11. M. Youle A. Mocroft M. Johnson et al. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures Antiviral Ther 4 Suppl. 1 1999 18-19
12. E. Seminari F. Maggiolo P. Villani et al. Efavirenz, nelfinavir and stvaudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors J Acquir Immune Defic Syndr 22 1999 453-460
13. M.A. Albrecht R.J. Bosch S.M. Hammer et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection N Engl J Med 345 2001 398-407
14. N. Lee R.S. Hogg B. Yip et al. Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy J Infect Dis 188 2003 137-141
15. J.R. King E.P. Acosta E. Chadwick et al. Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients Pediatr Infect Dis J 22 3 2003 239-244
16. DAIDS toxicity table for grading severity of pediatric adverse experiences. Available at: http://pactg:cure@roc.s-3.com/members/ download/pedtoxb.doc. Accessed March 28, 2002.
17. G.L. Drusano J.A. Bilello D.S. Stein et al. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic and pharmacologic variables J Infect Dis 178 1998 360-367
18. S. Rusconi S. La Seta Catamancio P. Citterio et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors Antimicrob Agents Chemother 44 2000 1328-1332
19. A. Mocroft A.N. Phillips V. Miller et al. The use of and response to 2nd-line protease inhibitor regimens: Results from the EuroSIDA study AIDS 15 2001 201-209
20. G.J. Moyle E. Wilkins C. Leen et al. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use AIDS 14 2000 1453-1454
21. J. Lawrence D.L. Mayers K. Huppler Hullsiek et al. Structured treatment interruptions in patients with multidrug-resistant human immunodeficiency virus N Engl J Med 349 2003 837-846
22. L. Ruiz E. Ribera A. Bonjoch et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene study J Infect Dis 188 2003 977-985
23. S.G. Deeks T. Wrin T. Liegler et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-therapy in HIV-infected patients with detectable viremia N Engl J Med 344 2001 472-480
24. A. Viganò S. Vella M. Saresella et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume AIDS 14 2000 251-261
25. A.M.C. Van Rossum H.J. Scherpbier E.G. Van Lochem et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status AIDS 15 2001 2267-2275
26. D.M. Gibb A. Newberry N. Klein et al. Immune repopulation after HAART in previously untreated HIV-1-infected children Lancet 355 2000 1331-1332
27. X. Sàez-Llorens A. Violari C.O. Deetz et al. Forty-eight-week evaluation of lopinavir/rotonavir, a new protease inhibitor in human immunodeficiency virus-infected children Pediatr Infect Dis J 22 2003 216-223
28. D.C. Watson J.J. Farley Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1 Pediatr Infect Dis J 18 1999 682-689
29. B. Yoffe A.S. Bagri T. Tran et al. Hyperlipasemia associated with hepatitis C virus Dig Dis Sci 48 8 2003 1648-1653
30. M. Loignon M. Martin E. Toma High rate of thyroid autoimmunity and disfunctions in HIV infected adults receiving highly active antiretroviral therapy Antiviral Ther 6 Suppl. 4 2001 55
31. J. Vincent A. Penfornis A. Schillo et al. Sequential occurrence of thyroid autoantibodies and Graves disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients J Clin Endocrinol Metab 85 2000 4254-4257